Stephen Ezell and Nigel Cory argue in The Hill that the United States should use the visit to Washington by Canada's new prime minister to push it to change its damaging approach to pharmaceutical patent applications, known as the “promise doctrine.” This approach has revoked 24 patents on 20 innovative drugs, costing over $1.1 billion in lost sales in the life sciences sector. It also undermines Canada's overall innovation performance, given the drop in investment in research and development by the life sciences sector in Canada.
